Healthcare Industry News: HSMN NewsFeed
News Release - November 26, 2008
Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of DirectorsMIAMI, Nov. 26 -- (Healthcare Sales & Marketing Network) -- Thomas K. Equels, President and Managing Director of the Equels Law Firm, has been elected to the board of directors for Hemispherx BioPharma, Inc. (Amex: HEB ), a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based disorders.
Equels' legal practice is devoted to litigation, with particular emphasis on civil racketeering, business torts and commercial matters. Prior to his board election, Equels served as Hemispherx BioPharma's litigation counsel.
For more than 25 years, Equels has represented national and state governments, and companies in the banking, insurance, aviation, pharmaceutical, construction and development industries. He has extensive experience in complex litigation matters including:
-- Obtained a $26.8 million judgment in 2008 in a breach of contract action against Bear Stearns, for the Delaware Insurance Commissioner, related to an insolvent insurance company.
-- Obtained a $15 million judgment in 2005 against boy band guru Lou Pearlman of Trans Continental Records, Inc.
-- Obtained a $44 million judgment against Manuel Noriega for public money he misappropriated from the Republic of Panama.
-- Recovered more than $100 million misappropriated and money laundered overseas by former insiders of a now defunct insurance company being liquidated by the State of Delaware's Insurance Commissioner.
-- Obtained and collected a $10.6 million judgment against the FDIC for breach of contract involving a client's purchase of a national mortgage company owned by a failed savings and loan.
-- Prosecuted a bank fraud claim against an international lender, which resulted in a jury awarding $2.6 million damages for fraud and an order invalidating a $9 million mortgage.
Equels earned a law degree with high honors from the Florida State University School of Law and earned a bachelor of arts degree, summa cum laude, from Troy State University. He is a member of The Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers.
About the Equels Law Firm
The Equels Law Firm has established itself as one of Florida's most effective and experienced law firms in the areas of complex litigation, government, business torts and personal injury law. The Equels Law Firm attorneys in Miami, Orlando and Tallahassee are known for providing high-quality, timely, efficient and personalized service to its local, national and international clients, whether representing them in either federal and state court or before federal, state or local governments. You can learn more about the Equels Law Firm at www.equelslaw.com or by calling Thomas Equels at (305) 859-7700.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N InjectionŽ (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, AmpligenŽ and Oragens. AmpligenŽ and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N InjectionŽ). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
Source: Equels Law Firm
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.